35
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      A round table discussion: clinical landscape of trastuzumab deruxtecan in breast cancer: a retrospective and prospective view

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The treatment landscape of breast cancer has been greatly changed by the innovative targeting therapies. Antibody-drug conjugates (ADCs) with a representative of trastuzumab deruxtecan (T-DXd) are the most successful ones. The revolutionary next-generation design of ADC transformed to the unprecedented clinical data. The DESTINY-BREAST01 and DESTINY-BREAST03 trials have changed the standard of care for HER2-positve metastatic breast cancer (MBC). At the same time the clinical data of T-DXd in HER2-postive patients with brain metastasis (BM) is numerously gaining and challenging the current treatment concept for central nerve system (CNS) involved disease. The DESTINY-BREAST series trials have quickly expanded to first-line (1L) and early setting of breast cancer. The newly reported positive result of DESTINY-BREAST04 trial has also opening the door of human epidermal growth factor receptor 2 (HER2)-low era. The breast cancer experts are facing a world of massive data and rapidly changing. Therefore, round table discussion meeting is a great way to share the information and options of among oncologists. This time, the breast cancer experts in China gathered to discuss the important clinical advances of T-DXd and its impact to clinical practice. The meeting minutes were recorded and organized as the review article. This would provide insights to better understanding of the current data and shape the further research directions of breast cancer.

          Related collections

          Most cited references48

          • Record: found
          • Abstract: found
          • Article: not found

          Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

          Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor. In a phase 1 dose-finding study, a majority of the patients with advanced HER2-positive breast cancer had a response to trastuzumab deruxtecan (median response duration, 20.7 months). The efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab emtansine requires confirmation.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

            Among breast cancers without human epidermal growth factor receptor 2 (HER2) amplification, overexpression, or both, a large proportion express low levels of HER2 that may be targetable. Currently available HER2-directed therapies have been ineffective in patients with these "HER2-low" cancers.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

              Patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who have disease progression after therapy with multiple HER2-targeted agents have limited treatment options. Tucatinib is an investigational, oral, highly selective inhibitor of the HER2 tyrosine kinase.
                Bookmark

                Author and article information

                Journal
                Transl Breast Cancer Res
                Transl Breast Cancer Res
                TBCR
                Translational Breast Cancer Research
                AME Publishing Company
                2218-6778
                31 October 2022
                2022
                : 3
                : 32
                Affiliations
                [1]deptKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology , Peking University Cancer Hospital & Institute , Beijing, China
                Author notes

                Contributions: (I) Conception and design: X Liang; (II) Administrative support: X Liang, G Song; (III) Provision of study materials or patients: All authors; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

                Correspondence to: Guohong Song; Xu Liang. Department of Breast Oncology, Peking University Cancer Hospital & Institute, 52 Fucheng Road, Haidian District, Beijing 100142, China. Email: songguohong918@ 123456hotmail.com ; liang_xu7788@ 123456163.com .

                Experts participating in the discussion (sorted by surname):
Chunfang Hao (Tumor Hospital of Tianjin Medical University); Zefei Jiang (Fifth Medical Center of Chinese PLA General Hospital); Qiang Liu (Sun Yat-sen Memorial Hospital of Sun Yat-sen University); Tao Sun (Liaoning Cancer Hospital); Shusen Wang (Sun Yat-sen University Cancer Center); Tao Wang (Fifth Medical Center of PLA General Hospital); Xiaojia Wang (Cancer Hospital Affiliated to Chinese Academy of Sciences); Min Yan (The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital); Ying Yan (Peking University Cancer Hospital & Institute); Yongmei Yin (the First Affiliation Hospital with Nanjing Medical University); Peng Yuan (Cancer Hospital of Chinese Academy of Medical Sciences); Yueping Liu (The Fourth Hospital of Hebei Medical University); Kun Wang (Guangdong Provincial People’s Hospital); Jiayi Chen (Ruijin Hospital, Shanghai Jiaotong University School of Medicine); Qingyuan Zhang (Harbin Medical University Cancer Hospital); Xu Liang (Peking University Cancer Hospital & Institute).

                Article
                tbcr-03-32
                10.21037/tbcr-22-45
                11093087
                38751531
                50d0164b-41a6-4a02-bc1e-fe2c003bff33
                2022 Translational Breast Cancer Research. All rights reserved.

                Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0.

                History
                : 02 September 2022
                : 20 October 2022
                Categories
                Review Article

                her2-postive,breast cancer,her2-low,trastuzumab deruxtecan (t-dxd),brain metastasis (bm)

                Comments

                Comment on this article